PALM CITY, FL--(Marketwired - April 29, 2014) - GelStat Corporation (PINKSHEETS: GSAC), a company engaged in the research, development, marketing and branding of innovative Over-the-Counter (OTC) consumer healthcare products, is pleased to announce the launch of Chews 2 Lose, its natural, sugar-free appetite suppressant gum with the name that says it all. The product is initially being offered direct-to-consumers at our website www.Chew2lose.com.
In recent trials of almost 100 consumers, we found that people's appetites were suppressed for up to 4 hours with no negative side effects. The average user reduced their calorie intake dramatically and binge eating was almost entirely eliminated, hence the brand's appropriate and catchy slogans of "Chew more... eat less" and "Beat the cheat" with this exciting new gum. The company went through numerous iterations to create the perfect flavor and chew-ability and has already started positioning the brand as the perfect "crutch" to help consumers take back control of their eating regardless of the diet plan they're on to prevent between or after meal snacking and binge eating.
Larry Gershman, Gelstat's CEO, said, "There are over 200 diet plans in the U.S. marketplace alone and Chews 2 Lose fills a huge void by being the ultimate support product for the 75 million people on a diet who constantly go off their plan by eating between or after meals; hence, consuming more calories. Chews 2 Lose has a proprietary blend of proven appetite suppressing herbs and vitamins, including the rare South African Hoodia Gordonii (used by the African bushmen for centuries to quell their hunger when they go off hunting for days in the bush) and 5-htp (which triggers the release of mood enhancing Serotonin to relieve hunger pains)... making it one of the most effective products in the market today. The Company is just now starting to present the product to major retail outlets and has already launched an engaging direct to the consumer website www.Chew2Lose.com. Expect to see a number of exciting new flavors and line extensions in the coming months as the brand takes hold in the marketplace!"
Make sure you are first to receive timely information on GelStat Corporation when it hits the newswire. Sign up for GelStat's email news alert system today at: http://ir.stockpr.com/gelstat/request-information
ABOUT GELSTAT CORPORATION
GelStat Corporation is a publicly traded company trading under the symbol ("GSAC") that is engaged in research, development, marketing and branding of innovative over-the-counter (OTC) consumer healthcare products addressing very large markets. The Company's initial products include GelStat Migraine, GelStat Sleep, Chews 2 Lose and All Natural Speed. The Company also has a suite of additional healthcare products in various stages of development that address large consumer markets.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, expects the market for migraine therapies to grow from $3.3 billion in 2011 to $5.8 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The total over-the-counter market for sleep aids alone reached $604 million in 2008, an increase of 9 percent over 2007, according to Packaged Facts, a division of Rockville, Md.-based Market Research Group.
According to Marketdata Enterprises, Inc., a leading independent market research publisher of "off-the-shelf" studies about service industries since 1979, an estimated 75 million dieters spent $2.7 billion in 2010 on diet pills and meal replacements.
According an article published by Companies and Markets.com, the US energy drinks market is estimated to have increased by 60% over the past four years, hitting an estimated value of $12.5 billion in 2012. The industry is expected to continue this growth path, by rising to a valuation of $21.5 billion by 2017.
For more information, visit www.gelstat.com.
Safe Harbor Statement
This press release and the shareholder letter contains forward-looking statements including pursuing strategic relationships, building and leveraging a direct-to consumer platform to launch new products, acquiring or licensing the rights to products with proven science, growing organically and achieving each of the goals mentioned above. Forward-looking statements can be identified by words such as "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects" and similar references to future periods.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the failure of our products to be accepted, failure to obtain partners to market and distribute our products, unanticipated delays in launching website or failure of the website to generate revenues, our inability to find a target to acquire on mutually acceptable terms, and the inability to get our reports prepared and filed timely as a result of unforeseen audit issues.
Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.